AG regimen

DRUG4 trials

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University, Tianjin Medical University Cancer Institute and Hospital, The First Affiliated Hospital with Nanjing Medical University, Zhejiang Provincial People's Hospital

Conditions

LDRTNeoadjuvant ChemotherapyPD-1 InhibitorPD-L1Pancreatic Adenocarcinoma ResectablePancreatic CancerPancreatic Cancer, AdultProterizumab

Phase 1

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

RecruitingNCT07312422

Zhejiang Provincial People's HospitalLDRT, Pancreatic Cancer, PD-1 Inhibitor +2

Start: 2025-09-30End: 2026-10-30Target: 10Updated: 2026-01-26

Phase 2

AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Not yet recruitingNCT06938503

Tianjin Medical University Cancer Institute and HospitalPancreatic Cancer, Adult

Start: 2025-04-21End: 2028-04-28Target: 48Updated: 2025-04-22

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

Not yet recruitingNCT07277452

The First Affiliated Hospital with Nanjing Medical UniversityPancreatic Cancer, Adult

Start: 2025-12-10End: 2029-12-10Target: 156Updated: 2025-12-11

Phase 3

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

CompletedNCT03750669

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNeoadjuvant Chemotherapy, Pancreatic Adenocarcinoma Resectable

Start: 2018-10-20End: 2025-03-01Updated: 2025-05-13

Related Papers

Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial.

2025-10-092 citations